Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma
Abstract Objectives The aim of this study is to evaluate the prevalence and prognostic significance of anaplastic lymphoma kinase ( ALK ) and c-ros oncogene 1 ( ROS1 ) rearrangement in never-smokers with surgically resected lung adenocarcinoma. Methods We retrospectively analyzed 162 consecutive nev...
Gespeichert in:
| Veröffentlicht in: | Lung cancer (Amsterdam, Netherlands) Netherlands), 2014-03, Vol.83 (3), p.389-395 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 395 |
|---|---|
| container_issue | 3 |
| container_start_page | 389 |
| container_title | Lung cancer (Amsterdam, Netherlands) |
| container_volume | 83 |
| creator | Kim, Min Hwan Shim, Hyo Sup Kang, Dae Ryong Jung, Ji Ye Lee, Chang Young Kim, Dae Joon Lee, Jin Gu Bae, Mi Kyung Kim, Hye Ryun Lim, Sun Min Kim, Eun Young Park, Ji Soo Chung, Kyung Young Kim, Hyun-Jung Kim, Joo Hang Cho, Byoung Chul |
| description | Abstract Objectives The aim of this study is to evaluate the prevalence and prognostic significance of anaplastic lymphoma kinase ( ALK ) and c-ros oncogene 1 ( ROS1 ) rearrangement in never-smokers with surgically resected lung adenocarcinoma. Methods We retrospectively analyzed 162 consecutive never-smokers who underwent curative resection for stage IB to IIIA lung adenocarcinoma at a single institution. We concurrently analyzed mutations in the epidermal growth factor receptor ( EGFR ) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog ( KRAS ) genes, and investigated ALK rearrangements by fluorescence in situ hybridization assay. ROS1 rearrangement was also determined in all triple ( EGFR/KRAS/ALK )-negative tumors. Results Of 162 never smokers with lung adenocarcinoma, 14 (8.6%) and 5 (3.1%) had ALK and ROS1 rearrangements, respectively. Nineteen of the 74 (25.7%) EGFR and KRAS mutation-negative patients were fusion-positive ( ALK or ROS1 fusion). Fusion-positive patients tended to have shorter median disease-free survival (DFS) than fusion-negative patients (28.0 vs. 33.9 months; p = 0.128). In multivariate analysis, fusion-positive patients had significantly poorer DFS than fusion-negative patients after adjustment for age, sex, T stage, N stage, and adjuvant chemotherapy use ( p = 0.022; hazard ratio, 2.11; 95% confidence interval, 1.19–4.30). The first recurrence sites were not significantly different between fusion-positive and fusion-negative patients in this study. Conclusion This study shows significantly poorer DFS of ALK or ROS1 fusion-positive lung adenocarcinoma in never-smokers after curative surgery. |
| doi_str_mv | 10.1016/j.lungcan.2014.01.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1501837590</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169500214000063</els_id><sourcerecordid>1501837590</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-8710a1f802f2b7be40bd3f34d22a7fa65e79b996527c387551d324cb4b0352da3</originalsourceid><addsrcrecordid>eNqFkk2PFCEQhonRuOPqT9BwMfHSbQH9edFsJn7FSTZx9UxoqB6Z7YYRutfM0X8u7bSaeJELCXmqeHkoQp4yyBmw6uUhH2a318rlHFiRA8sBxD2yYU3Ns0YIfp9sEtdmJQC_II9iPACwmkH7kFzwoqh4UYkN-bEdrLNaDVQ5Q4_B752Pk9XUjschnU_Wu0h9T692H38hn65vGA2oQlBujyO6KVLrqMM7DFkc_S2GSL_b6SuNc9gvnYdT4iPqCQ1dMlNl0HmtgrbOj-oxedCrIeKTdb8kX96--bx9n-2u333YXu0yXZQwZU2KrljfAO95V3dYQGdELwrDuap7VZVYt13bViWvtWjqsmRG8EJ3RQei5EaJS_Li3Dc98tuMcZKjjRqHQTn0c5SsBNaIumwhoeUZ1cHHGLCXx2BHFU6SgVzsy4Nc7cvFvgQmk_1U92y9Yu5GNH-qfutOwPMVUDGZ6ZNDbeNfrknJq6ZK3Oszh0nIncUgo7boNBobkkhpvP1vlFf_dNDrR9_iCePBz8El25LJyCXIm2VUlklhBaSVov4ELoO7tA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1501837590</pqid></control><display><type>article</type><title>Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Kim, Min Hwan ; Shim, Hyo Sup ; Kang, Dae Ryong ; Jung, Ji Ye ; Lee, Chang Young ; Kim, Dae Joon ; Lee, Jin Gu ; Bae, Mi Kyung ; Kim, Hye Ryun ; Lim, Sun Min ; Kim, Eun Young ; Park, Ji Soo ; Chung, Kyung Young ; Kim, Hyun-Jung ; Kim, Joo Hang ; Cho, Byoung Chul</creator><creatorcontrib>Kim, Min Hwan ; Shim, Hyo Sup ; Kang, Dae Ryong ; Jung, Ji Ye ; Lee, Chang Young ; Kim, Dae Joon ; Lee, Jin Gu ; Bae, Mi Kyung ; Kim, Hye Ryun ; Lim, Sun Min ; Kim, Eun Young ; Park, Ji Soo ; Chung, Kyung Young ; Kim, Hyun-Jung ; Kim, Joo Hang ; Cho, Byoung Chul</creatorcontrib><description>Abstract Objectives The aim of this study is to evaluate the prevalence and prognostic significance of anaplastic lymphoma kinase ( ALK ) and c-ros oncogene 1 ( ROS1 ) rearrangement in never-smokers with surgically resected lung adenocarcinoma. Methods We retrospectively analyzed 162 consecutive never-smokers who underwent curative resection for stage IB to IIIA lung adenocarcinoma at a single institution. We concurrently analyzed mutations in the epidermal growth factor receptor ( EGFR ) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog ( KRAS ) genes, and investigated ALK rearrangements by fluorescence in situ hybridization assay. ROS1 rearrangement was also determined in all triple ( EGFR/KRAS/ALK )-negative tumors. Results Of 162 never smokers with lung adenocarcinoma, 14 (8.6%) and 5 (3.1%) had ALK and ROS1 rearrangements, respectively. Nineteen of the 74 (25.7%) EGFR and KRAS mutation-negative patients were fusion-positive ( ALK or ROS1 fusion). Fusion-positive patients tended to have shorter median disease-free survival (DFS) than fusion-negative patients (28.0 vs. 33.9 months; p = 0.128). In multivariate analysis, fusion-positive patients had significantly poorer DFS than fusion-negative patients after adjustment for age, sex, T stage, N stage, and adjuvant chemotherapy use ( p = 0.022; hazard ratio, 2.11; 95% confidence interval, 1.19–4.30). The first recurrence sites were not significantly different between fusion-positive and fusion-negative patients in this study. Conclusion This study shows significantly poorer DFS of ALK or ROS1 fusion-positive lung adenocarcinoma in never-smokers after curative surgery.</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/j.lungcan.2014.01.003</identifier><identifier>PMID: 24462463</identifier><identifier>CODEN: LUCAE5</identifier><language>eng</language><publisher>Oxford: Elsevier Ireland Ltd</publisher><subject>Adenocarcinoma - diagnosis ; Adenocarcinoma - genetics ; Adenocarcinoma - mortality ; Anaplastic lymphoma kinase ; Biological and medical sciences ; C-ros oncogene 1 ; DNA Mutational Analysis ; Gene Rearrangement - genetics ; Hematologic and hematopoietic diseases ; Hematology, Oncology and Palliative Medicine ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lung adenocarcinoma ; Lung Neoplasms - diagnosis ; Lung Neoplasms - genetics ; Lung Neoplasms - mortality ; Medical sciences ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Mutation - genetics ; Neoplasm Staging ; Never-smokers ; Pneumology ; Pneumonectomy ; Prognosis ; Protein-Tyrosine Kinases - genetics ; Proto-Oncogene Proteins - genetics ; Proto-Oncogene Proteins p21(ras) ; Pulmonary/Respiratory ; ras Proteins - genetics ; Receptor Protein-Tyrosine Kinases - genetics ; Receptor, Epidermal Growth Factor - genetics ; Recurrence ; Retrospective Studies ; Smoking ; Survival Analysis ; Tobacco, tobacco smoking ; Toxicology ; Tumors ; Tumors of the respiratory system and mediastinum</subject><ispartof>Lung cancer (Amsterdam, Netherlands), 2014-03, Vol.83 (3), p.389-395</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2014 Elsevier Ireland Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-8710a1f802f2b7be40bd3f34d22a7fa65e79b996527c387551d324cb4b0352da3</citedby><cites>FETCH-LOGICAL-c450t-8710a1f802f2b7be40bd3f34d22a7fa65e79b996527c387551d324cb4b0352da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.lungcan.2014.01.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28387686$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24462463$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Min Hwan</creatorcontrib><creatorcontrib>Shim, Hyo Sup</creatorcontrib><creatorcontrib>Kang, Dae Ryong</creatorcontrib><creatorcontrib>Jung, Ji Ye</creatorcontrib><creatorcontrib>Lee, Chang Young</creatorcontrib><creatorcontrib>Kim, Dae Joon</creatorcontrib><creatorcontrib>Lee, Jin Gu</creatorcontrib><creatorcontrib>Bae, Mi Kyung</creatorcontrib><creatorcontrib>Kim, Hye Ryun</creatorcontrib><creatorcontrib>Lim, Sun Min</creatorcontrib><creatorcontrib>Kim, Eun Young</creatorcontrib><creatorcontrib>Park, Ji Soo</creatorcontrib><creatorcontrib>Chung, Kyung Young</creatorcontrib><creatorcontrib>Kim, Hyun-Jung</creatorcontrib><creatorcontrib>Kim, Joo Hang</creatorcontrib><creatorcontrib>Cho, Byoung Chul</creatorcontrib><title>Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma</title><title>Lung cancer (Amsterdam, Netherlands)</title><addtitle>Lung Cancer</addtitle><description>Abstract Objectives The aim of this study is to evaluate the prevalence and prognostic significance of anaplastic lymphoma kinase ( ALK ) and c-ros oncogene 1 ( ROS1 ) rearrangement in never-smokers with surgically resected lung adenocarcinoma. Methods We retrospectively analyzed 162 consecutive never-smokers who underwent curative resection for stage IB to IIIA lung adenocarcinoma at a single institution. We concurrently analyzed mutations in the epidermal growth factor receptor ( EGFR ) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog ( KRAS ) genes, and investigated ALK rearrangements by fluorescence in situ hybridization assay. ROS1 rearrangement was also determined in all triple ( EGFR/KRAS/ALK )-negative tumors. Results Of 162 never smokers with lung adenocarcinoma, 14 (8.6%) and 5 (3.1%) had ALK and ROS1 rearrangements, respectively. Nineteen of the 74 (25.7%) EGFR and KRAS mutation-negative patients were fusion-positive ( ALK or ROS1 fusion). Fusion-positive patients tended to have shorter median disease-free survival (DFS) than fusion-negative patients (28.0 vs. 33.9 months; p = 0.128). In multivariate analysis, fusion-positive patients had significantly poorer DFS than fusion-negative patients after adjustment for age, sex, T stage, N stage, and adjuvant chemotherapy use ( p = 0.022; hazard ratio, 2.11; 95% confidence interval, 1.19–4.30). The first recurrence sites were not significantly different between fusion-positive and fusion-negative patients in this study. Conclusion This study shows significantly poorer DFS of ALK or ROS1 fusion-positive lung adenocarcinoma in never-smokers after curative surgery.</description><subject>Adenocarcinoma - diagnosis</subject><subject>Adenocarcinoma - genetics</subject><subject>Adenocarcinoma - mortality</subject><subject>Anaplastic lymphoma kinase</subject><subject>Biological and medical sciences</subject><subject>C-ros oncogene 1</subject><subject>DNA Mutational Analysis</subject><subject>Gene Rearrangement - genetics</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lung adenocarcinoma</subject><subject>Lung Neoplasms - diagnosis</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - mortality</subject><subject>Medical sciences</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Mutation - genetics</subject><subject>Neoplasm Staging</subject><subject>Never-smokers</subject><subject>Pneumology</subject><subject>Pneumonectomy</subject><subject>Prognosis</subject><subject>Protein-Tyrosine Kinases - genetics</subject><subject>Proto-Oncogene Proteins - genetics</subject><subject>Proto-Oncogene Proteins p21(ras)</subject><subject>Pulmonary/Respiratory</subject><subject>ras Proteins - genetics</subject><subject>Receptor Protein-Tyrosine Kinases - genetics</subject><subject>Receptor, Epidermal Growth Factor - genetics</subject><subject>Recurrence</subject><subject>Retrospective Studies</subject><subject>Smoking</subject><subject>Survival Analysis</subject><subject>Tobacco, tobacco smoking</subject><subject>Toxicology</subject><subject>Tumors</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkk2PFCEQhonRuOPqT9BwMfHSbQH9edFsJn7FSTZx9UxoqB6Z7YYRutfM0X8u7bSaeJELCXmqeHkoQp4yyBmw6uUhH2a318rlHFiRA8sBxD2yYU3Ns0YIfp9sEtdmJQC_II9iPACwmkH7kFzwoqh4UYkN-bEdrLNaDVQ5Q4_B752Pk9XUjschnU_Wu0h9T692H38hn65vGA2oQlBujyO6KVLrqMM7DFkc_S2GSL_b6SuNc9gvnYdT4iPqCQ1dMlNl0HmtgrbOj-oxedCrIeKTdb8kX96--bx9n-2u333YXu0yXZQwZU2KrljfAO95V3dYQGdELwrDuap7VZVYt13bViWvtWjqsmRG8EJ3RQei5EaJS_Li3Dc98tuMcZKjjRqHQTn0c5SsBNaIumwhoeUZ1cHHGLCXx2BHFU6SgVzsy4Nc7cvFvgQmk_1U92y9Yu5GNH-qfutOwPMVUDGZ6ZNDbeNfrknJq6ZK3Oszh0nIncUgo7boNBobkkhpvP1vlFf_dNDrR9_iCePBz8El25LJyCXIm2VUlklhBaSVov4ELoO7tA</recordid><startdate>20140301</startdate><enddate>20140301</enddate><creator>Kim, Min Hwan</creator><creator>Shim, Hyo Sup</creator><creator>Kang, Dae Ryong</creator><creator>Jung, Ji Ye</creator><creator>Lee, Chang Young</creator><creator>Kim, Dae Joon</creator><creator>Lee, Jin Gu</creator><creator>Bae, Mi Kyung</creator><creator>Kim, Hye Ryun</creator><creator>Lim, Sun Min</creator><creator>Kim, Eun Young</creator><creator>Park, Ji Soo</creator><creator>Chung, Kyung Young</creator><creator>Kim, Hyun-Jung</creator><creator>Kim, Joo Hang</creator><creator>Cho, Byoung Chul</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140301</creationdate><title>Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma</title><author>Kim, Min Hwan ; Shim, Hyo Sup ; Kang, Dae Ryong ; Jung, Ji Ye ; Lee, Chang Young ; Kim, Dae Joon ; Lee, Jin Gu ; Bae, Mi Kyung ; Kim, Hye Ryun ; Lim, Sun Min ; Kim, Eun Young ; Park, Ji Soo ; Chung, Kyung Young ; Kim, Hyun-Jung ; Kim, Joo Hang ; Cho, Byoung Chul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-8710a1f802f2b7be40bd3f34d22a7fa65e79b996527c387551d324cb4b0352da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adenocarcinoma - diagnosis</topic><topic>Adenocarcinoma - genetics</topic><topic>Adenocarcinoma - mortality</topic><topic>Anaplastic lymphoma kinase</topic><topic>Biological and medical sciences</topic><topic>C-ros oncogene 1</topic><topic>DNA Mutational Analysis</topic><topic>Gene Rearrangement - genetics</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lung adenocarcinoma</topic><topic>Lung Neoplasms - diagnosis</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - mortality</topic><topic>Medical sciences</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Mutation - genetics</topic><topic>Neoplasm Staging</topic><topic>Never-smokers</topic><topic>Pneumology</topic><topic>Pneumonectomy</topic><topic>Prognosis</topic><topic>Protein-Tyrosine Kinases - genetics</topic><topic>Proto-Oncogene Proteins - genetics</topic><topic>Proto-Oncogene Proteins p21(ras)</topic><topic>Pulmonary/Respiratory</topic><topic>ras Proteins - genetics</topic><topic>Receptor Protein-Tyrosine Kinases - genetics</topic><topic>Receptor, Epidermal Growth Factor - genetics</topic><topic>Recurrence</topic><topic>Retrospective Studies</topic><topic>Smoking</topic><topic>Survival Analysis</topic><topic>Tobacco, tobacco smoking</topic><topic>Toxicology</topic><topic>Tumors</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Min Hwan</creatorcontrib><creatorcontrib>Shim, Hyo Sup</creatorcontrib><creatorcontrib>Kang, Dae Ryong</creatorcontrib><creatorcontrib>Jung, Ji Ye</creatorcontrib><creatorcontrib>Lee, Chang Young</creatorcontrib><creatorcontrib>Kim, Dae Joon</creatorcontrib><creatorcontrib>Lee, Jin Gu</creatorcontrib><creatorcontrib>Bae, Mi Kyung</creatorcontrib><creatorcontrib>Kim, Hye Ryun</creatorcontrib><creatorcontrib>Lim, Sun Min</creatorcontrib><creatorcontrib>Kim, Eun Young</creatorcontrib><creatorcontrib>Park, Ji Soo</creatorcontrib><creatorcontrib>Chung, Kyung Young</creatorcontrib><creatorcontrib>Kim, Hyun-Jung</creatorcontrib><creatorcontrib>Kim, Joo Hang</creatorcontrib><creatorcontrib>Cho, Byoung Chul</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Min Hwan</au><au>Shim, Hyo Sup</au><au>Kang, Dae Ryong</au><au>Jung, Ji Ye</au><au>Lee, Chang Young</au><au>Kim, Dae Joon</au><au>Lee, Jin Gu</au><au>Bae, Mi Kyung</au><au>Kim, Hye Ryun</au><au>Lim, Sun Min</au><au>Kim, Eun Young</au><au>Park, Ji Soo</au><au>Chung, Kyung Young</au><au>Kim, Hyun-Jung</au><au>Kim, Joo Hang</au><au>Cho, Byoung Chul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><addtitle>Lung Cancer</addtitle><date>2014-03-01</date><risdate>2014</risdate><volume>83</volume><issue>3</issue><spage>389</spage><epage>395</epage><pages>389-395</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><coden>LUCAE5</coden><abstract>Abstract Objectives The aim of this study is to evaluate the prevalence and prognostic significance of anaplastic lymphoma kinase ( ALK ) and c-ros oncogene 1 ( ROS1 ) rearrangement in never-smokers with surgically resected lung adenocarcinoma. Methods We retrospectively analyzed 162 consecutive never-smokers who underwent curative resection for stage IB to IIIA lung adenocarcinoma at a single institution. We concurrently analyzed mutations in the epidermal growth factor receptor ( EGFR ) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog ( KRAS ) genes, and investigated ALK rearrangements by fluorescence in situ hybridization assay. ROS1 rearrangement was also determined in all triple ( EGFR/KRAS/ALK )-negative tumors. Results Of 162 never smokers with lung adenocarcinoma, 14 (8.6%) and 5 (3.1%) had ALK and ROS1 rearrangements, respectively. Nineteen of the 74 (25.7%) EGFR and KRAS mutation-negative patients were fusion-positive ( ALK or ROS1 fusion). Fusion-positive patients tended to have shorter median disease-free survival (DFS) than fusion-negative patients (28.0 vs. 33.9 months; p = 0.128). In multivariate analysis, fusion-positive patients had significantly poorer DFS than fusion-negative patients after adjustment for age, sex, T stage, N stage, and adjuvant chemotherapy use ( p = 0.022; hazard ratio, 2.11; 95% confidence interval, 1.19–4.30). The first recurrence sites were not significantly different between fusion-positive and fusion-negative patients in this study. Conclusion This study shows significantly poorer DFS of ALK or ROS1 fusion-positive lung adenocarcinoma in never-smokers after curative surgery.</abstract><cop>Oxford</cop><pub>Elsevier Ireland Ltd</pub><pmid>24462463</pmid><doi>10.1016/j.lungcan.2014.01.003</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-5002 |
| ispartof | Lung cancer (Amsterdam, Netherlands), 2014-03, Vol.83 (3), p.389-395 |
| issn | 0169-5002 1872-8332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1501837590 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adenocarcinoma - diagnosis Adenocarcinoma - genetics Adenocarcinoma - mortality Anaplastic lymphoma kinase Biological and medical sciences C-ros oncogene 1 DNA Mutational Analysis Gene Rearrangement - genetics Hematologic and hematopoietic diseases Hematology, Oncology and Palliative Medicine Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lung adenocarcinoma Lung Neoplasms - diagnosis Lung Neoplasms - genetics Lung Neoplasms - mortality Medical sciences Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Mutation - genetics Neoplasm Staging Never-smokers Pneumology Pneumonectomy Prognosis Protein-Tyrosine Kinases - genetics Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins p21(ras) Pulmonary/Respiratory ras Proteins - genetics Receptor Protein-Tyrosine Kinases - genetics Receptor, Epidermal Growth Factor - genetics Recurrence Retrospective Studies Smoking Survival Analysis Tobacco, tobacco smoking Toxicology Tumors Tumors of the respiratory system and mediastinum |
| title | Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T04%3A06%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20and%20prognostic%20implications%20of%20ALK%20and%20ROS1%20rearrangements%20in%20never-smokers%20with%20surgically%20resected%20lung%20adenocarcinoma&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=Kim,%20Min%20Hwan&rft.date=2014-03-01&rft.volume=83&rft.issue=3&rft.spage=389&rft.epage=395&rft.pages=389-395&rft.issn=0169-5002&rft.eissn=1872-8332&rft.coden=LUCAE5&rft_id=info:doi/10.1016/j.lungcan.2014.01.003&rft_dat=%3Cproquest_cross%3E1501837590%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1501837590&rft_id=info:pmid/24462463&rft_els_id=S0169500214000063&rfr_iscdi=true |